These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 19123458

  • 1. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN.
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [Abstract] [Full Text] [Related]

  • 2. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [Abstract] [Full Text] [Related]

  • 3. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [Abstract] [Full Text] [Related]

  • 4. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ.
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [Abstract] [Full Text] [Related]

  • 5. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.
    Guglielmi C, Martelli M, Federico M, Zinzani PL, Vitolo U, Bellesi G, Santini G, Tarella C, Zallio F, Pregno P, Di Renzo N, Resegotti L, Italian Intergroup for Lymphomas.
    Haematologica; 2001 Sep; 86(9):941-50. PubMed ID: 11532622
    [Abstract] [Full Text] [Related]

  • 6. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, Thompson CA, Markovic SN.
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [Abstract] [Full Text] [Related]

  • 7. New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.
    Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN.
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):376-83. PubMed ID: 19883776
    [Abstract] [Full Text] [Related]

  • 8. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 9. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
    Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef IN, Markovic SN.
    Bone Marrow Transplant; 2004 Feb 20; 33(3):291-8. PubMed ID: 14676784
    [Abstract] [Full Text] [Related]

  • 10. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
    Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G.
    Arch Immunol Ther Exp (Warsz); 2010 Apr 20; 58(2):131-41. PubMed ID: 20191326
    [Abstract] [Full Text] [Related]

  • 11. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio.
    Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN.
    Am J Hematol; 2010 Nov 20; 85(11):896-9. PubMed ID: 20842639
    [Abstract] [Full Text] [Related]

  • 12. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
    Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Markovic SN.
    Bone Marrow Transplant; 2006 May 20; 37(9):865-71. PubMed ID: 16532015
    [Abstract] [Full Text] [Related]

  • 13. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation.
    Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM.
    Bone Marrow Transplant; 2008 Apr 20; 41(8):715-20. PubMed ID: 18195687
    [Abstract] [Full Text] [Related]

  • 14. Absolute lymphocyte count predicts overall survival in follicular lymphomas.
    Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Call TG, Porrata LF.
    Br J Haematol; 2006 Sep 20; 134(6):596-601. PubMed ID: 16889618
    [Abstract] [Full Text] [Related]

  • 15. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study.
    Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Porrata LF.
    Br J Haematol; 2008 Jun 20; 141(6):792-8. PubMed ID: 18410454
    [Abstract] [Full Text] [Related]

  • 16. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK, Chung JS, Sung-Yong O, Lee GW, Kim SG, Seol YM, Shin HJ, Choi YJ, Cho GJ, Shin DH, Yun EY.
    Ann Hematol; 2010 Oct 20; 89(10):985-91. PubMed ID: 20428871
    [Abstract] [Full Text] [Related]

  • 17. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A.
    J Clin Oncol; 2008 Jul 01; 26(19):3166-75. PubMed ID: 18490650
    [Abstract] [Full Text] [Related]

  • 18. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M, Watanabe K, Fukuda T, Miura O.
    Anticancer Res; 2017 May 01; 37(5):2655-2662. PubMed ID: 28476841
    [Abstract] [Full Text] [Related]

  • 19. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
    Li YL, Pan YY, Jiao Y, Ning J, Fan YG, Zhai ZM.
    Ann Hematol; 2014 Apr 01; 93(4):617-26. PubMed ID: 24141331
    [Abstract] [Full Text] [Related]

  • 20. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.
    Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP.
    Am J Hematol; 2010 Mar 01; 85(3):160-3. PubMed ID: 20131304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.